Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $355.00, but opened at $382.60. Genmab A/S shares last traded at $384.00, with a volume of 275 shares.
Genmab A/S Stock Down 5.1%
The company has a 50-day moving average price of $328.22 and a 200 day moving average price of $288.27. The firm has a market capitalization of $23.20 billion, a PE ratio of 29.55 and a beta of 0.75. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44.
About Genmab A/S
Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.
Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies.
Featured Stories
- Five stocks we like better than Genmab A/S
- AI Chip Demand Gives Linde a New Growth Catalyst
- Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion
- 3 Sectors Where Volatility Is Creating Entry Points, Not Exit Signals
- D-Wave’s Gate-Model Tech Notches a Major Milestone
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
